Fludarabine drug page Clinical trials

Trials with Fludarabine

Every colorectal cancer trial that includes this drug. Those looking for patients come first.

31Trials
13Recruiting
3Countries
1.959Planned patients

Showing 1–20 of 31

TCR1188-ABC Cells in KRAS-mutated Cancers
Recruiting Phase 1 30 patients NCT07594067

This is a Phase I, open-label dose finding study to assess the safety, manufacturing feasibility, and preliminary efficacy of TCR1188-ABC cells in patients with KRAS-mutated cancers. Initially, patients with KRAS G12V mutation positive met…

United States Aug 2026 – Jul 2042 Interventional
Combined with: Tocilizumab
Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")
Recruiting Phase 1 28 patients NCT07411599

To find the highest dose of NK cells that can be given by vein and intraperitoneally (given directly into the abdominal cavity) in combination with cetuximab to patients with colorectal cancer that has spread to the peritoneum.

United States Apr 2026 – Nov 2030 Interventional
Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
Recruiting Phase 1 72 patients NCT07523529

This is a multicenter, open-label, Phase 1/2 master protocol evaluating autologous dual-target CAR-T cell therapy in adults with advanced solid cancers. After central biomarker screening, each participant is assigned the best-matched dual-…

China Mar 2026 – Mar 2028 Interventional
Combined with: Cyclophosphamide
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
Recruiting Phase 1 100 patients NCT06885697

Background: Mesothelioma is an aggressive cancer that grows in the linings of the body; this can include the membranes that line the heart, lungs, and internal organs. Mesothelin (MSLN) is a protein that appears in high numbers in many tu…

United States Jul 2025 – Jun 2044 Interventional
Combined with: Cyclophosphamide
Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer
Recruiting Phase 1 85 patients NCT06530303

This Phase I/II study evaluates the safety and efficacy of autologous tumor-infiltrating lymphocytes (TIL) therapy combined with Pembrolizumab (Keytruda) and Aldesleukin (interleukin-2, IL-2) immunotherapy in patients with advanced or meta…

China Sept 2024 – Dec 2026 Interventional
ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)
Recruiting Phase 1 30 patients NCT06415487

ACE2016 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor …

United States, Taiwan Aug 2024 – Mar 2027 Interventional
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
Recruiting Phase 1 351 patients NCT06241456

This is a phase 1 study designed to evaluate the safety, tolerability, and antitumor activity of FT825 (also known as ONO-8250) with or without monoclonal antibody therapy following chemotherapy in participants with advanced human epiderma…

United States Jan 2024 – May 2044 Interventional
T Cell Receptor T Cells for Advanced KRAS G12V-mutant Non-small Cell Lung Cancer, Pancreas Cancer, Colon Cancer
Recruiting Phase 1 24 patients NCT06043713

This phase I trial studies the side effects and best dose of autologous CD8+ and CD4+ transgenic T cells expressing high affinity KRASG12V mutation-specific T cell receptors (FH-A11KRASG12V-TCR) and to see how well they work in treating pa…

United States Dec 2023 – Jan 2028 Interventional
HRYZ-T101 Injection for HPV18 Positive Solid Tumor
Recruiting Phase 1 32 patients NCT05952947

A multicenter, open label, single arm dose escalation phase I study to evaluate the safety, tolerability, and efficacy of HRYZ-T101 injection for HPV18 positive solid tumor. The study will investigate RP2D of HRYZ-T101 TCR-T cell injection.

China Nov 2023 – Feb 2028 Interventional
HER2 Targeted HypoSti.CAR-T Cells in HER2 Positive Advanced Solid Tumors
Recruiting Phase 1 30 patients NCT05681650

Chimeric antigen receptor modified T (CAR-T) cell therapy still has multiple difficulties in solid tumors, such as absence of tumor specific antigens, complex immunosuppressive tumor microenvironment, and tumor heterogeneity. In this study…

China Oct 2023 – Dec 2026 Interventional
Combined with: Cyclophosphamide
Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid Tumors
Recruiting Phase 1 15 patients NCT05693844

In preclinical study, investigators have demonstrated that the newly developed pan-T booster (harbouring CD40 agonist and one T cell costimulator agonist) co-expressing MSLN CAR T cell possess more powerful antitumor activity than previous…

China Jan 2023 – Dec 2026 Interventional
Combined with: Cyclophosphamide
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Recruiting Phase 1 110 patients NCT03190941

Background: A new cancer therapy involves taking white blood cells from a person, growing them in the lab, genetically modifying them, then giving them back to the person. This therapy is called gene transfer using anti-KRAS G12V mTCR cel…

United States Sept 2017 – Jun 2028 Interventional
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Recruiting Phase 2 332 patients NCT01174121

Background: The NCI Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving the cells back to the patient. These c…

United States Aug 2010 – Dec 2029 Interventional
Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors
Not yet recruiting Phase 1 36 patients NCT06027983

This phase Ib study aims to assess the safety and feasibility of combination of chimeric receptor T cells with trastuzumab in patients with HER2+ solid tumors, with further expansion of study population in HER2+ metastatic breast cancer on…

Nov 2026 – Dec 2027 Interventional
Phase 1 Study of NW-301V TCR-T Cells in Advanced Solid Tumors With KRAS G12V Mutation
Not yet recruiting Phase 1 66 patients NCT07875920

This is a single-arm, multicenter, open-label, Phase 1a/1b dose-escalation and dose-expansion study designed to evaluate the safety, preliminary antitumor activity, and pharmacokinetic/pharmacodynamic (PK/PD) characteristics of NW-301V, an…

China Oct 2026 – Mar 2033 Interventional
Combined with: CyclophosphamideNW-301V
TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors
Not yet recruiting Phase 1 25 patients NCT07342738

This is a single-arm, Multicenter, open-label clinical study aimed at evaluating the safety and efficacy of TCR-T injection in patients with advanced solid tumors induced by KRAS mutations.

China Feb 2026 – Feb 2029 Interventional
Combined with: Cyclophosphamide
CD73/AXL Targeted HypoSti.CAR-T Cells in CD73/AXL Positive Advanced/Metastatic Solid Tumors
Not yet recruiting Phase 1 30 patients NCT06939270

In this single-center, single-arm,prospective, open-label, phase 1/2 study, the safety and efficacy of novel autologous hypoxia-activated CAR-T cell therapy targeting CD73 and AXL ( CD73/AXL.HypoSti.CAR-T) will be evaluated in patients wit…

China May 2025 – May 2028 Interventional
Combined with: Cyclophosphamide
Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma
Not yet recruiting Phase 1 66 patients NCT06505551

This is a phase 1/2, open-label, single arm, multicenter study in patients with advanced or metastatic HPV16- or HPV52-positive carcinomas who have progressed after at least one line of systemic therapy, including but not limited to combin…

Oct 2024 – Dec 2028 Interventional
Combined with: CyclophosphamideSCG142
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
Ongoing, not recruiting Phase 1 210 patients NCT06253520

Background: Many cancer cells produce substances called antigens that are unique to each cancer. These antigens stimulate the body s immune responses. One approach to treating these cancers is to take disease-fighting white blood cells fr…

United States May 2024 – Feb 2029 Interventional
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
Ongoing, not recruiting Phase 2 20 patients NCT03935893

This is a Phase 2 study to evaluate the efficacy of a non-myeloablative lymphodepleting preparative regimen followed by infusion of autologous TIL and high-dose aldesleukin in patients with locally advanced, recurrent, or metastatic cancer…

United States Dec 2019 – Jun 2038 Interventional

Where the recruiting trials are